The cost effectiveness of teriparatide as a first-line treatment for glucocorticoid-induced and postmenopausal osteoporosis patients in Sweden

by Murphy Daniel R, Smolen Lee J, Klein Timothy M, Klein Robert W
Published 2012-10-01

Estimated economic benefits from low-frequency administration of atypical antipsychotics in treatment of schizophrenia: a decision model

by Furiak Nicolas M, Gahn James C, Klein Robert W, Camper Stephen B, Summers Kent H
Published 2012-11-01

Modeling screening, prevention, and delaying of Alzheimer's disease: an early-stage decision analytic model

by Siemers Eric R, Kahle-Wrobleski Kristin, Klein Robert W, Furiak Nicolas M, Sarpong Eric, Klein Timothy M
Published 2010-04-01

Cost-effectiveness model comparing olanzapine and other oral atypical antipsychotics in the treatment of schizophrenia in the United States

by Smolen Lee J, Klein Robert W, Ascher-Svanum Haya, Furiak Nicolas M, Lawson Anthony H, Conley Robert R, Culler Steven D
Published 2009-04-01